E. A. Belongia, Variable influenza vaccine effectiveness by subtype: a 693 systematic review and meta-analysis of test-negative design studies, Lancet Infect, vol.694

. Dis, , vol.16, pp.942-951, 2016.

H. Xie, H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza 696 Vaccines and Head-to-head Comparison between Human and Ferret Antisera 697 derived, Antigenic Maps. Sci Rep, vol.5, p.15279, 2015.

B. Flannery, Early estimates of seasonal influenza vaccine effectiveness-699

, United States, MMWR Morb Mortal Wkly Rep, vol.16, issue.1, pp.10-15, 2015.

B. S. Chambers, K. Parkhouse, T. M. Ross, K. Alby, and S. E. Hensley,

, Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift 703 during the 2014-2015 Influenza Season, Cell Rep, vol.12, pp.1-6, 2015.

A. C. Tricco, Comparing influenza vaccine efficacy against mismatched 705 and matched strains: a systematic review and meta-analysis, BMC Medicine, vol.706, p.153, 2013.

S. L. Epstein, Prior H1N1 influenza infection and susceptibility of Cleveland 708

, Family Study participants during the H2N2 pandemic of 1957: an experiment of 709 nature, J Infect Dis, vol.193, pp.49-53, 2006.

Z. Wang, Recovery from severe H7N9 disease is associated with diverse 711 response mechanisms dominated by CD8? T cells, Nat Commun, vol.6, p.6833, 2015.

S. Sridhar, Cellular immune correlates of protection against symptomatic 714 pandemic influenza, Nat Med, vol.19, pp.1305-1312, 2013.

T. M. Wilkinson, Preexisting influenza-specific CD4+ T cells correlate with 716 disease protection against influenza challenge in humans, Nat Med, vol.18, pp.274-280, 2012.

A. C. Hayward, Natural T Cell-mediated Protection against Seasonal and 719

, Pandemic Influenza. Results of the Flu Watch Cohort Study, Am J Respir Crit, vol.720

, Care Med, vol.191, pp.1422-1431, 2015.

O. T. Gorman, W. J. Bean, Y. Kawaoka, and R. G. Webster, Evolution of the 722 nucleoprotein gene of influenza A virus, J Virol, vol.64, issue.4, pp.1487-1497, 1990.

H. M. Machkovech, T. Bedford, M. A. Suchard, and J. D. Bloom, Positive 724

, Selection in CD8+ T-Cell Epitopes of Influenza Virus Nucleoprotein Revealed by 725 a Comparative Analysis of Human and Swine Viral Lineages, J Virol, vol.89, pp.11275-726, 2015.

A. Hessel, MVA vectors expressing conserved influenza proteins protect 728 mice against lethal challenge with H5N1, H9N2 and H7N1 viruses, PLoS One. 729, vol.11, issue.2, p.88340, 2014.

C. Wu, Systematic identification of immunodominant CD8+ T-cell 731 responses to influenza A virus in HLA-A2 individuals, Proc Natl Acad Sci, vol.108, pp.9178-9183, 2011.

G. Spagnoli, Broadly neutralizing antiviral responses induced by a single-765 molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope 766 nanoparticles, Sci. Rep, vol.7, 2017.

Y. Li, Enhancing immunogenicity and transmission-blocking activity of 768 malaria vaccines by fusing Pfs25 to IMX313 multimerization technology, Sci 769 Rep, vol.6, p.18848, 2016.

W. Smith, C. H. Andrewes, and P. P. Laidlaw, A virus obtained from influenza 771 patients, Lancet, vol.222, pp.66-68, 1933.

J. R. Gallagher, U. Torian, D. M. Mccraw, and A. K. Harris, Structural studies of 773 influenza virus RNPs by electron microscopy indicate molecular contortions 774 within NP supra-structures, J Struct Biol, vol.197, pp.294-307, 2017.

Q. Ye, R. M. Krug, and Y. J. Tao, The mechanism by which influenza A virus 776 nucleoprotein forms oligomers and binds RNA, Nature, vol.21, issue.7122, pp.1078-82

, Epub, 2006.

S. H. Naik, Cutting Edge: Generation of Splenic CD8+ and CD8? Dendritic 779

, Cell Equivalents in Fms-Like Tyrosine Kinase 3 Ligand Bone Marrow Cultures, J 780 Immunol, vol.1, issue.11, pp.6592-6597, 2005.

T. K. Berthoud, Potent CD8+ T-cell immunogenicity in humans of a novel 785 heterosubtypic influenza A vaccine, MVA-NP+M1, Clin Infect Dis, vol.1, issue.1, pp.1-7, 2011.

P. G. Thomas, R. Keating, D. J. Hulse-post, and P. C. Doherty, Cell-mediated 788 protection in influenza infection, Emerg Infect Dis, vol.12, pp.48-54, 2006.

S. C. Gilbert, Advances in the development of universal influenza vaccines. 790 Influenza Other Respir Viruses, vol.7, pp.750-758, 2013.

R. Nachbagauer and F. Krammer, Universal influenza virus vaccines and 792 therapeutic antibodies, Clin Microbiol Infect, vol.23, pp.222-228, 2017.

A. E. Fiore, Prevention and control of influenza with vaccines: 794 recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep, vol.59, issue.8, pp.1-62, 2010.

V. Usonis, Central European Vaccination Advisory Group (CEVAG) 797 guidance statement on recommendations for influenza vaccination in children, BMC Infect Dis, vol.798, p.168, 2010.

R. Bodewes, Vaccination against human influenza A/H3N2 virus prevents 800 the induction of heterosubtypic immunity against lethal infection with avian 801 influenza A/H5N1 virus, PLoS One, vol.4, p.5538, 2009.

J. B. Ulmer, Heterologous protection against influenza by injection of DNA 803 encoding a viral protein, Science, vol.259, pp.1745-1749, 1993.

J. B. Ulmer, Protective CD4+ and CD8+ T cells against influenza virus 805 induced by vaccination with nucleoprotein DNA, J Virol, vol.72, pp.5648-5653, 1998.

T. M. Fu, Dose dependence of CTL precursor frequency induced by a DNA 807 vaccine and correlation with protective immunity against influenza virus 808 challenge, J. Immunol, vol.162, pp.4163-4170, 1999.

S. L. Epstein, DNA Vaccine Expressing Conserved Influenza Virus Proteins 810

, Protective Against H5N1 Challenge Infection in Mice, Emerg Infect Dis, vol.8, pp.796-811, 2002.

S. L. Epstein and G. E. Price, Cross-protective immunity to influenza A viruses. Differences were assessed by 1-way ANOVA followed by Tukey's Multiple 923 comparison test with 95% confidence intervals; p<0.05 is considered significant 924 (****p<0.0001) or by two-way ANOVA followed by a Dunnett's multiple 925 comparison test